Abstract
E2F transcription factors, including E2F3, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P=0.0022) and cause-specific survival (P=0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of E2F3-positive nuclei identified within their prostate cancers (up to 20, 21–40%, etc.), there is an increasingly significant association between E2F3 staining and risk of death both for overall survival (P=0.0014) and for cause-specific survival (P=0.0004). Multivariate analyses select E2F3 expression as an independent factor predicting overall survival (unstratified P=0.0103, stratified P=0.0086) and cause-specific survival (unstratified P=0.0288, stratified P=0.0072). When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB–E2F3–EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bostwick DG and Foster CS . (1999). Semin. Urol. Oncol., 17, 222–272.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K . (2003). EMBO J., 22, 5323–5335.
Brooks JD, Bova GS and Isaacs WB . (1995). Prostate, 26, 35–39.
Chakravarti A, Heydon K, Wu CL, Hammond E, Pollack A, Roach M, Wolkov H, Okunieff P, Cox J, Fontanesi J, Abrams R, Pilepich M and Shipley W . (2003). J. Clin. Oncol., 21, 3328–3334.
Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J and Cooper CS . (1997). Oncogene, 15, 2233–2239.
Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine AJ . (1994). Cancer Res., 54, 794–799.
Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J and Foster CS . (1999). Am. J. Pathol., 154, 137–144.
Cox D and Oakes D . (1984). Analysis of Survival Data. Chapman-Hall: New York.
Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS and Cooper CS . (2004). Oncogene, 23, 1627–1630.
Foster CS . (2000). Prostate Suppl., 9, 4–14.
Foster CS, Bostwick DG, Bonkhoff H, Damber JE, van der KT, Montironi R and Sakr WA . (2000). Scand. J. Urol. Nephrol. Suppl., 19–43.
Foster CS and Sakr WA . (2001). Curr. Diagn. Pathol., 7, 4–14.
Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT and Honn KV . (1995). Oncogene, 11, 1395–1398.
Giangrande PH, Hallstrom TC, Tunyaplin C, Calame K and Nevins JR . (2003). Mol. Cell. Biol., 23, 3707–3720.
Greene FL, Balch CM, Fleming ID, Fritz A, Haller DG, Morrow M and Page DL . (2002). AJCC Cancer Staging Handbook 6th ed. Springer: New York.
Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW and Srivastava S . (1995). J. Urol., 154, 414–421.
Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D’Amico M, Pestell RG, West M and Nevins JR . (2003). Nat. Genet., 34, 226–230.
Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S and Lees JA . (2000). Genes Dev., 14, 690–703.
Kaplan EL and Meier P . (1958). J. Am. Stat. Assoc., 53, 457–481.
Kibel AS and Isaacs WB . (2000). Urology, 55, 316–322.
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM . (2003). Proc. Natl. Acad. Sci. USA, 100, 11606–11611.
Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E and Shimada K . (2002). Jpn. J. Cancer Res., 93, 767–773.
Lapointe J, Chunde L, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD and Pollack JR . (2004). Proc. Natl. Acad. Sci. USA, 101, 811–816.
Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I and Camara-Lopes LH . (2001). Mod. Pathol., 14, 428–436.
Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS and Nevins JR . (1998). Genes Dev., 12, 2120–2130.
Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM and Grossman SR . (2001). Proc. Natl. Acad. Sci. USA, 98, 4455–4460.
Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and Helin K . (2001). Genes Dev., 15, 267–285.
Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C . (1999). Clin. Cancer Res., 5, 2082–2088.
Shaaban AM, Sloane JP, West CR, Moore FR, Jarvis C, Williams EM and Foster CS . (2002). Am. J. Surg. Pathol., 26, 421–430.
Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, Ross M, Linehan WM, Birdsall S, Shipley J and Cooper CS . (1996). Hum. Mol. Genet., 5, 1333–1338.
Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G and Cooper CS . (2001). Oncogene, 20, 178–187.
Sobin LH and Wittekind C . (1997). TNM Classification of Malignant Tumours. Wiley-Liss: New York, pp 170–173.
Theodorescu D, Broder SR, Boyd JC, Mills SE and Frierson Jr HF . (1997). J. Urol., 158, 131–137.
Tomovska S, Richter J, Suess K, Wagner U, Rozenblum E, Gasser TC, Moch H, Mihatsch MJ, Sauter G and Schraml P . (2001). Int. J. Oncol., 18, 1239–1244.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM . (2002). Nature, 419, 624–629.
Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, Nuckolls F, Giangrande P, Wright FA, Field SJ, Greenberg ME, Orkin S, Nevins JR, Robinson ML and Leone G . (2001). Nature, 414, 457–462.
Acknowledgements
This work is supported by the National Cancer Research Institute, the Cancer Research UK, the Medical Research Council and TR Golden Charitable Trust. We thank Christine Bell for typing this manuscript. Alison Falconer is supported by a grant from the Community Fund through the AICR.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Foster, C., Falconer, A., Dodson, A. et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23, 5871–5879 (2004). https://doi.org/10.1038/sj.onc.1207800
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207800
Keywords
This article is cited by
-
Verify the Function of a Potential Growth-Regulating Gene in Marine Bivalve Using a Candidate Model Organism Mulinia lateralis
Journal of Ocean University of China (2023)
-
ITRAQ-based proteomic analysis reveals possible target-related proteins in human adrenocortical adenomas
BMC Genomics (2019)
-
The essential role of WD repeat domain 77 in prostate tumor initiation induced by Pten loss
Oncogene (2018)
-
HOXB9 promotes endometrial cancer progression by targeting E2F3
Cell Death & Disease (2018)
-
Nanos genes and their role in development and beyond
Cellular and Molecular Life Sciences (2018)